Print

Lay Description

NRG-GI011 (LAP100) is a Phase III randomized trial assessing the addition of dose-escalated radiotherapy to chemotherapy in LAPC.

Category

  • Cancers and Other Neoplasms
IRB Number
STUDY00001932
NCT Number
NCT06958328

Eligibility

Eligible Ages
18 - 99
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups

Study Contact


Frances Crawford
210-450-5037
crawfordf1@uthscsa.edu

Myrna Montenegro
210-450-5954
montenegro@uthscsa.edu

Kathleen Rodriguez
210-450-1365
rodriguezk3@uthscsa.edu

Benjamin Schleif
210-450-1366
schleifb@uthscsa.edu

Morgan Seekatz
210-450-1133
seekatz@uthscsa.edu


mccsolidtumor@uthscsa.edu

Principal Investigator
Amy Le